Exonate Plans 'CLEAR-DE' Phase IIb Clinical Trial of Lead Candidate EXN407 for Diabetic Eye Disease

Exonate plans 'CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical trial for its lead candidate EXN407.

Exonate plans to initiate phase 2b CLEAR-DE trial for EXN407 topical formulation for NPDR

The first-in-class, twice-daily topical formulation is intended for the treatment of non-proliferative diabetic retinopathy and diabetic macular edema.

Exonate to launch phase 2b trial of EXN407 for diabetic eye disease

CLEAR-DE study to assess topical therapy for non-proliferative diabetic retinopathy

Propelling R&D for Novel Retinal Therapies Through Innovative Clinical Trial Design

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.